The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
Marksans' OTC Famotidine Tablets USP are acid reducers
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Subscribe To Our Newsletter & Stay Updated
